LABORATORY RESEARCH Pro-Oncogenic Factors miR-23b- and miR-27b Are Regulated by Her2/Neu, EGF, and TNFα in Breast Cancer Scientists identified microRNA (miR)-23b and miR-27b as miRNAs that are highly upregulated in human breast cancer. They found that engineered knockdown of miR-23b and miR-27b substantially repressed breast cancer growth. [Cancer Res] Abstract | Press Release The Mitotic Kinase Aurora-A Promotes Distant Metastases by Inducing Epithelial-to-Mesenchymal Transition in ERα+ Breast Cancer Cells Researchers demonstrated that constitutive activation of Raf-1 oncogenic signaling induces stabilization and accumulation of Aurora-A mitotic kinase that ultimately drives the transition from an epithelial to a highly invasive mesenchymal phenotype in estrogen receptor α-positive (ERα+) breast cancer cells. [Oncogene] Abstract Chromatin Effector Pygo2 Regulates Mammary Tumor Initiation and Heterogeneity in MMTV-Wnt1 Mice Investigators showed that epithelia-specific ablation of Pygopus 2 (Pygo2) in MMTV-Wnt1 transgenic mice results in delayed mammary ductal elongation, but the hyperbranching phenotype, aberrant accumulation of stem/progenitor-like cells, and canonical Wnt signaling output are largely unaffected. [Oncogene] Abstract The Prognostic Significance and Value of Cyclin D1, CDK4 and p16 in Human Breast Cancer The material consisted of 102 formalin-fixed human breast cancer samples, in which cyclin D1, CDK4 and p16 expression was evaluated immunohistochemically. The amounts of cyclin D1 mRNA present were analyzed by quantitative real time PCR. [Breast Cancer Res] Abstract | Full Article Loss of E-Cadherin Is Not a Necessity for Epithelial to Mesenchymal Transition in Human Breast Cancer Epithelial to mesenchymal transition (EMT) is typically defined by the acquisition of a spindle cell morphology in combination with loss of E-cadherin and upregulation of mesenchymal markers. However, by studying E-cadherin inactivation in 38 human breast cancer cell lines, the authors noted that not all cell lines that had undergone EMT had concomitantly lost E-cadherin expression. [Breast Cancer Res Treat] Abstract Involvement of Early Growth Response Factors in TNFα-Induced Aromatase Expression in Breast Adipose Scientists showed that the early growth response (Egr) transcription factors play an important role in the TNFα-induced signaling pathway resulting in elevated distal promoter I.4 transcription. TNFα treatment of breast adipose fibroblasts increases mRNA levels of all four Egr family members, with EGR2 being the most highly expressed. [Breast Cancer Res Treat] Abstract The Heterochronic MicroRNA let-7 Inhibits Cell Motility by Regulating the Genes in the Actin Cytoskeleton Pathway in Breast Cancer Researchers report that the expression levels of three let-7 family members, let-7a, let-7b, and let-7g, were significantly decreased in breast cancer patients with lymph node metastasis compared to those without lymph node metastasis. [Mol Cancer Res] Abstract CLINICAL RESEARCH Persistence in Patients with Breast Cancer Treated with Tamoxifen or Aromatase Inhibitors: A Retrospective Database Analysis Researchers analyzed the persistence with tamoxifen and aromatase inhibitors in postmenopausal women with hormone-receptor-positive breast cancer and identified determinants of non-persistence. [Breast Cancer Res Treat] Abstract Final Results from Phase II Trial of Neoadjuvant Docetaxel and Capecitabine Given Sequentially or Concurrently for HER2-Negative Breast Cancers Patients with stage I to stage IIIC, human epidermal growth factor receptor 2-negative (HER2−) breast cancer were randomly assigned to receive either docetaxel followed by capecitabine or docetaxel administered concomitantly with capecitabine. [Clin Breast Cancer] Abstract |